Kim Kelderman

Kim Kelderman serves as President and CEO of Bio-Techne, a life science tools company that provides critical reagents, instruments, and diagnostic solutions to pharmaceutical, biotechnology, academic, and clinical researchers worldwide. The company operates through two segments: Protein Sciences (producing recombinant proteins, antibodies, immunoassays, and other reagents under the R&D Systems and Novus Biologicals brands) and Diagnostics and Genomics (molecular diagnostics, spatial biology, and clinical assays). Bio-Techne's competitive advantage lies in the quality and breadth of its reagent catalog — the company produces over 500,000 products that are essential inputs for biological research. When a scientist needs a specific protein or antibody for an experiment, Bio-Techne is often the only source for the highest-quality version. This creates strong recurring revenue and pricing power. The company has expanded through acquisitions into spatial biology (Advanced Cell Diagnostics, Lunaphore), proteomics (Protein Simple), and cell therapy manufacturing tools. Key stock drivers include pharmaceutical and biotech R&D spending, academic research funding, spatial biology adoption, cell and gene therapy manufacturing growth, instrument placement trends, and the competitive dynamics with larger life science tools companies like Danaher (Abcam), Thermo Fisher, and Merck KGaA.